Capital Performance Advisors LLP Myriad Genetics Inc Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Myriad Genetics Inc stock. As of the latest transaction made, Capital Performance Advisors LLP holds 41 shares of MYGN stock, worth $737. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41Holding current value
$737% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MYGN
# of Institutions
238Shares Held
92.6MCall Options Held
117KPut Options Held
113K-
Black Rock Inc. New York, NY15.2MShares$273 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$181 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA8.26MShares$149 Million0.04% of portfolio
-
Camber Capital Management LP Boston, MA5.5MShares$98.9 Million3.72% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny4.4MShares$79.1 Million0.05% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.45B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...